Compare INSM & BG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | BG |
|---|---|---|
| Founded | 1988 | 1818 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 24.9B |
| IPO Year | 2000 | 2023 |
| Metric | INSM | BG |
|---|---|---|
| Price | $162.30 | $129.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 24 | 7 |
| Target Price | ★ $200.48 | $132.29 |
| AVG Volume (30 Days) | ★ 2.1M | 1.8M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.18% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.91 |
| Revenue | N/A | ★ $70,329,000,000.00 |
| Revenue This Year | $174.73 | $35.60 |
| Revenue Next Year | $65.13 | $0.99 |
| P/E Ratio | ★ N/A | $26.17 |
| Revenue Growth | N/A | ★ 32.43 |
| 52 Week Low | $60.40 | $71.60 |
| 52 Week High | $212.75 | $131.50 |
| Indicator | INSM | BG |
|---|---|---|
| Relative Strength Index (RSI) | 60.93 | 62.64 |
| Support Level | $157.91 | $111.01 |
| Resistance Level | $167.01 | N/A |
| Average True Range (ATR) | 6.19 | 4.31 |
| MACD | 3.01 | 0.32 |
| Stochastic Oscillator | 84.92 | 82.92 |
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Bunge Global SA is an agribusiness solutions company, connecting farmers to consumers and delivering essential food, feed and fuel to the globe. The company segments include Soybean Processing and Refining; Softseed Processing and Refining; Other Oilseeds Processing and Refining; Grain Merchandising and Milling; and Corporate and Other. It generates maximum revenue from the Soybean Processing and Refining segment, which includes integrated business principally involved in the purchase, storage, transportation, processing, distribution, refining, marketing, and sale of soybeans and soybean related products, as well as biodiesel and fertilizer production and distribution. Geographically, the company operates in United States, Switzerland, Netherlands, and Rest of the World.